Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price
Confirmatory Trial Seeks To Show Survival Advantage
Krazati was approved for second-line NSCLC with labeling that positions it ahead of Lumakras on efficacy, but not safety. Pricing is slightly higher than for Amgen’s drug.
